FEMASYS INC. - COMMON STOCK

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

15 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

14 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. EU MDR Final Audit Successfully Completed

26 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

25 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

11 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

04 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

03 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

27 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

25 9 2023 17:25:04 提供 Nasdaq GlobeNewswire

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

20 9 2023 08:30:09 提供 Nasdaq GlobeNewswire

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 9 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

31 8 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

10 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

03 8 2023 08:45:00 提供 Nasdaq GlobeNewswire

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

27 7 2023 08:45:00 提供 Nasdaq GlobeNewswire

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

26 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

15 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

14 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

08 6 2023 08:30:00 提供 Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

11 5 2023 16:05:01 提供 Nasdaq GlobeNewswire